MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Abbott Laboratories

Gesloten

SectorGezondheidszorg

131.66 -0.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

131.22

Max

133.52

Belangrijke statistieken

By Trading Economics

Inkomsten

7.6B

9.2B

Verkoop

339M

11B

K/W

Sectorgemiddelde

17.363

63.778

EPS

1.34

Dividendrendement

1.78

Winstmarge

84.099

Werknemers

114,000

EBITDA

82M

3B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+6.28% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.78%

2.39%

Volgende Winsten

16 apr 2025

Volgende dividenddatum

15 mei 2025

Volgende Ex Dividend datum

15 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

7.8B

230B

Vorige openingsprijs

131.98

Vorige sluitingsprijs

131.66

Nieuwssentiment

By Acuity

27%

73%

81 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Abbott Laboratories Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 jan 2025, 19:03 UTC

Winsten

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22 jan 2025, 18:20 UTC

Winsten

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22 jan 2025, 12:45 UTC

Winsten

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

1 nov 2024, 14:15 UTC

Belangrijke Marktbewegers

Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update

1 nov 2024, 10:10 UTC

Belangrijke Marktbewegers

Reckitt Shares Surge After Baby Formula Lawsuit Win

31 okt 2024, 23:57 UTC

Populaire aandelen

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

31 okt 2024, 23:14 UTC

Belangrijke Marktbewegers

Abbott Laboratories Shares Rise After Baby-Formula Verdict

16 okt 2024, 12:03 UTC

Winsten

Abbott Laboratories 3Q Sales Top Expectations

1 feb 2025, 18:14 UTC

Top Nieuws

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22 jan 2025, 16:40 UTC

Top Nieuws
Winsten

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22 jan 2025, 15:20 UTC

Winsten

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22 jan 2025, 15:08 UTC

Winsten

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 jan 2025, 13:51 UTC

Winsten

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22 jan 2025, 13:39 UTC

Top Nieuws
Winsten

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 jan 2025, 12:02 UTC

Winsten

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22 jan 2025, 12:01 UTC

Winsten

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22 jan 2025, 12:01 UTC

Winsten

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs 4Q Net $9.23B >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs 4Q Sales $10.97B >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs 4Q Organic Sales Growth Up 8.8% >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs 4Q EPS $5.27 >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs 4Q Adj EPS $1.34 >ABT

22 jan 2025, 09:54 UTC

Populaire aandelen

Stocks to Watch Wednesday: Netflix, Oracle, Trump Media, Softbank -- WSJ

1 nov 2024, 17:33 UTC

Marktinformatie

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

16 okt 2024, 14:21 UTC

Top Nieuws
Winsten

Abbott Posts Solid Quarter. The Stock Is Rising. -- Barrons.com

16 okt 2024, 12:25 UTC

Winsten

Abbott Labs Beats Q3 Sales And Earnings Expectations, Raises Full-Year Outlook -- MarketWatch

16 okt 2024, 12:02 UTC

Top Nieuws
Winsten

Abbott Posts Solid Quarter. That Wasn't Enough to Lift Shares. -- Barrons.com

16 okt 2024, 11:59 UTC

Winsten

Abbott Earnings Edge Past Q3 Views, Led By Medical Devices -- IBD

16 okt 2024, 11:37 UTC

Winsten

Abbott Labs Sees 4Q Adj EPS $1.31-Adj EPS $1.37 >ABT

Peer Vergelijking

Prijswijziging

Abbott Laboratories Prognose

Koersdoel

By TipRanks

6.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 140.21 USD  6.28%

Hoogste 158 USD

Laagste 117 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Abbott Laboratories - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Technische score

By Trading Central

126.38 / 132.65Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

81 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.